Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Staszewski

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
The Journal of Clinical Investigation|March 23, 2000
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNAG P Rizzardi, R J De Boer, S Hoover, et al.
Antimicrobial Agents and Chemotherapy|April 4, 1998
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugsK Hertogs, M P de Béthune, V Miller, et al.
Lancet (London, England)|September 6, 2003
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studiesG Chêne, J A C Sterne, M May, et al.
International Journal of Antimicrobial Agents|March 13, 1999
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trialA M Been-Tiktak, C A Boucher, F Brun-Vezinet, et al.
Antiviral Therapy|January 18, 2005
Updated European recommendations for the clinical use of HIV drug resistance testingA M Vandamme, A Sönnerborg, M Ait-Khaled, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
The Journal of Clinical Investigation|March 23, 2000
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNAG P Rizzardi, R J De Boer, S Hoover, et al.
Antimicrobial Agents and Chemotherapy|April 4, 1998
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugsK Hertogs, M P de Béthune, V Miller, et al.
Lancet (London, England)|September 6, 2003
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studiesG Chêne, J A C Sterne, M May, et al.
International Journal of Antimicrobial Agents|March 13, 1999
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trialA M Been-Tiktak, C A Boucher, F Brun-Vezinet, et al.
Antiviral Therapy|January 18, 2005
Updated European recommendations for the clinical use of HIV drug resistance testingA M Vandamme, A Sönnerborg, M Ait-Khaled, et al.
Pageof 10